Taysha stops developing a gene therapy amid debate over FDA's stance on ultra-rare trials - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Taysha Gene Therapies discontinued development of a neurodegenerative therapy after the FDA again insisted on a potentially impossible study, the company said Tuesday. It’s yet another reminder of how difficult it is to bring medicines targeting ultra-rare co…